Submit Manuscript | http://medcraveonline.com Abbreviations: AMI: Antibody Mediated Immunity; PMNL: Polymorphonuclear Leucocytes; CMI: Cell-Mediated Immunity; : Chronic Mucocutaneous Candidiasis; GI: Gastrointestinal; NK: Natural Killer; GM-CSF: Granulocyte-Macrophage Colony Stimulating Factor; MPC: Mononuclear Phagocytic Cells; PRPs: Pattern Recognition Receptors; VVC: Vulvovaginal Candidiasis...

Recurrent vulvovaginal candidiasis (RVVC) is seen in 5% of women with Candida vaginitis. Use of fluconazole as prophylactic treatment has been suggested for RVVC. The aim of the present study was to evaluate the efficacy of fluconazole suppressive therapy in RVVC patients, as a randomized, placebo-controlled, double-blind prophylactic study. Among the 330 women with acute symptomatic vulvovagin...

recurrent vulvovaginal candidiasis (rvvc) is seen in 5% of women with candida vaginitis. use of fluconazole as prophylactic treatment has been suggested for rvvc. the aim of the present study was to evaluate the efficacy of fluconazole suppressive therapy in rvvc patients, as a randomized, placebo-controlled, double-blind prophylactic study. among the 330 women with acute symptomatic vulvovagin...

Background The novel echinocandin CD101 has stability properties amenable to topical formulation for use in the treatment of acute vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC). CD101 has demonstrated potent antifungal activity at pH 7, but assessment of its activity at the physiological pH of the vaginal environment is needed. Objectives To evaluate the antifungal activity of CD101...

Vulvovaginal candidiasis (VVC) is an insidious infection that afflicts a large proportion of women of all ages, and 5 to 8% of affected women experience recurrent VVC (RVVC). The aim of this study was to explore the possible importance of vaginal bacterial communities in reducing the risk of RVVC. The species composition and diversity of microbial communities were evaluated for 42 women with an...

It is estimated that 75% of all women will experience at least 1 episode of vulvovaginal candidiasis (VVC) during their lifetimes. Most patients with acute VVC can be treated with short-term regimens that optimize compliance. Since current topical and oral antifungals have shown comparably high efficacy rates, other issues should be considered in determining the most appropriate therapy. It is ...

Mannose-binding lectin (MBL) plays a key role in the human innate immune response. It has been shown that polymorphisms in the MBL2 gene, particularly at codon 54 (variant allele B; wild-type allele designated as A), impact upon host susceptibility to Candida infection. This systematic review and meta-analysis were performed to assess the association between MBL2 codon 54 genotype and vulvovagi...

Abstract Background Oteseconazole (VT-1161) is a novel, investigational oral therapy that currently under FDA review for the treatment of recurrent vulvovaginal candidiasis (RVVC). Susceptibility testing was performed on all viable clinical isolates collected from three Phase 3 studies to determine susceptibility causative pathogens oteseconazole versus current standard care, fluconazole. Metho...

The aim of the present study is to assess the clinical efficacy of a phytocompound with antimicotic properties (K-712, with the following 100 mg composition: 10 mg of oleoresin from Pseudowintera colorata at 30 percent concentration in Polygodial together with trace amounts of Olea europea) in recurrent vulvo-vaginal candidiasis (RVVC) as compared to an azole drug during a 12-month period: 6 mo...